Executives at Oasmia Pharmaceutical AB came to the J.P. Morgan Healthcare Conference (JPM) recently confident they had every chance of perking up investor interest in their story.
What are the chances that two guys with the same name but no family connection would co-found a company? The odds seem especially slim when the name isn’t just Smith or Jones but Radin – Andrew A., the CEO, and Andrew M., the chief business officer, to be exact.
Shares of Zafgen Inc. (NASDAQ:ZFGN) more than doubled early and trading was heavy after the Boston-based company reported positive efficacy results from the bestPWS ZAF-311 study of beloranib in patients with Prader-Willi syndrome (PWS).
SAN FRANCISCO – Growing a regional specialty pharma from the ground up is an ambitious goal, especially in Latin America, which has almost no publicly traded pure pharma players and only a handful of companies whose territories extend beyond the borders of a single country. Still, that was the aspiration of Grupo Biotoscana SL (GBT), which traveled last week to pitch its story to investors at the 34th J.P. Morgan Healthcare Conference (JPM).
SAN FRANCISCO – The National Immunotherapy Coalition (NIC) received a big plug this week from President Barack Obama and from organizers of the 34th Annual J.P. Morgan Healthcare Conference (JPM), where a panel on the project was featured late Wednesday.
SAN FRANCISCO – Anyone expecting to hear breaking news from PTC Therapeutics Inc. during its presentation at the J.P. Morgan Healthcare Conference (JPM) came away disappointed. The low-key presentation by CEO Stuart Peltz recounted the ex-U.S. commercial trajectory for Translarna (ataluren) in Duchenne muscular dystrophy (DMD) across the first full year, restated the company's plans for additional regulatory filings and repeated the company's mantra about the potential of Translarna to treat patients across multiple rare disease indications.
SAN FRANCISCO – Rough start for the year to the public markets? No worry for privately held Moderna Therapeutics Inc., which has no plans to go public this year, according to CEO Stéphane Bancel.
For the third straight year, money flowed like honey in the life sciences sector, with 468 life sciences M&As disclosed in 2015, according to the Thomson Reuters Deals Review, presented in conjunction with the 34th Annual J.P. Morgan Healthcare Conference.
Hours before the official kickoff of the 34th Annual J.P. Morgan Healthcare Conference (JPM) in San Francisco, Sanofi SA gave a big boost to partner Warp Drive Bio LLC in an amended collaboration that could exceed $750 million, while inking a second licensing deal with French biotech Innate Pharma SA.
The New York arm of Accelerator Corp. launched its second biopharma in less than a week as Lodo Therapeutics Corp. set out with a $17 million series A financing.
